Sacituzumab govitecan Antibody
Sacituzumab govitecan (IMMU-132) is a humanized Trop-2-targeting antibody-drug conjugate (ADC) for research into refractory, locally advanced, or metastatic cancers such as breast and urothelial carcinoma. Its anticancer activity and mechanism of action are studied in both in vitro cell-based assays and in vivo tumor models.
Product Specifications
Product Name Alternative
ADCs, Antibody-Drug Conjugates, AntibodyDrug Conjugates (ADCs), Antibody-Drug Conjugates (ADCs), AntibodyDrugConjugates, AntibodyDrugConjugates (ADCs), IMMU132, IMMU-132, IMMU 132, Sacituzumab govitecan, TROP2
Clonality
Recombinant
Conjugation
Unconjugated
Field of Research
Immunology & Inflammation
Concentration
6.48 mg/mL
Purity
95.00% (May vary between batches)
Molecular Weight
148.74 kDa
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC041398-500 1x 500 µL
BRCA1 (Breast Marker) (BRCA1/1398), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
